People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Pharmaceuticals, Other Technology, Other, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Translate Bio, Inc. | — | Biotechnology | Series C | $98.5M | $1.9B | 2016 |
| CalciMedica Subsidiary, Inc. | — | Biotechnology | Series B | $73.0M | $127.9M | 2014 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2013 |
| SpringLeaf Therapeutics, Inc. | — | Pharmaceuticals | Series B | $34.1M | $647.7M | 2011 |
| River Vision Development Corp. | — | Biotechnology | Series B | $33.1M | $198.4M | 2012 |
| Springbot, Inc. | — | Other Technology | Series A | $28.2M | $61.4M | 2013 |
| Tier One Holding Corp. | — | Other | Series B | $27.6M | $93.2M | 2016 |
| Slate Bio, Inc. | — | Biotech / Pharma | Seed | $4.8M | $29.9M | 2022 |
| Infinity Hall Hartford, LLC | — | Other | Seed | $4.7M | $7.0M | — |
| Transport Pharmaceuticals Inc | — | Pharmaceuticals | Pre-Seed | $1.7M | $9.5M | 2009 |
| Project Management Holdings Ltd | — | Other | Pre-Seed | $200K | $4.6M | 2010 |
Brian Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Mark Johnson | 1 | 22 |
| Michael Greeley | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| Wayne Hunter | 1 | 10 |
| Kevin Kelly | 1 | 10 |
| Alan Crane | 1 | 9 |
| David Gould | 1 | 7 |
| Ryan Schwarz | 1 | 7 |
| Rajeev Dadoo | 1 | 7 |
| Richard S. Kollender | 1 | 7 |
| Jeffrey McCarthy | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| John Creecy | 1 | 5 |
| Vikas Goyal | 1 | 5 |
| Kurt Graves | 1 | 5 |
| John Egan | 1 | 5 |
| Michael Dunn | 1 | 5 |
| Paul Friedman | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.